Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 5—May 2024
Research

Cross-Sectional Study of Q Fever Seroprevalence among Blood Donors, Israel, 2021

Nesrin Ghanem-Zoubi1Comments to Author , Yafit Atiya-Nasagi1, Evgeniy Stoyanov, Moran Szwarcwort, Basel Darawsha, Mical Paul, and Eilat Shinar
Author affiliations: Rambam Health Care Campus, Haifa, Israel (N. Ghanem-Zoubi, M. Szwarcwort, M. Paul); The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa (N. Ghanem-Zoubi, B. Darawsha, M. Paul); Israel Institute for Biological Research, Ness-Ziona, Israel (Y. Atiya-Nasagi); Magen David Adom National Blood Services, Ramat Gan, Israel (E. Stoyanov, E. Shinar)

Main Article

Table 1

Q fever antibody results in cross-sectional study of Q fever seroprevalence among blood donors, Israel, 2021

Antibody No. (%) participants
Negative Borderline, = 100 Positive, >200 200–800 >1,600
Phase II IgG 1,152 (78.2) 134 (9) 187 (12.6) 158 (10.7) 29 (1.9)
Phase I IgG 1,374 (93.2) 41 (2.7) 58 (3.9) 56 (3.8) 2 (0.1)

Main Article

1These authors contributed equally to this article.

Page created: March 07, 2024
Page updated: April 23, 2024
Page reviewed: April 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external